Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

• Becton, Dickinson and Company recently deployed the BD Vmax 160, a next-generation pharmacy automation robot, at Fairview Health Services, marking the first U.S. deployment of this technology to manage complex specialty therapies and refrigerated medications, which positions the company at the forefront of intelligent pharmacy automation.
• The company reported strong second-quarter results with earnings per share of $3.23, beating analyst estimates of $3.14, and revenue of $4.98 billion, which exceeded the consensus estimate of $4.89 billion, demonstrating robust operational performance and top-line growth of 5.4% year-over-year.
• With a current stock price of $179.45, Becton, Dickinson and Company offers a dividend yield of 2.30%, providing a steady income stream for investors, supported by a recent quarterly dividend of $1.05 per share paid to investors of record on September 9, 2026.
• Institutional investor confidence is high, with State Street Corp increasing its holdings by 8.5% in the second quarter and BlackRock Inc. establishing a new position valued at approximately $3.72 billion, indicating significant institutional accumulation of the stock.
• The company maintains a low beta of 0.21, suggesting that Becton, Dickinson and Company shares are less volatile than the broader market, which can provide a defensive characteristic for portfolios during periods of market uncertainty.